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Background: Osteoporosis is a metabolic disorder characterized by a reduction in bone mass and deterioration in
the microarchitectural structure of the bone, leading to a higher risk for spontaneous and fragility fractures.
The main aim was to study the differences between human bone from osteoporotic and osteoarthritic patients
about gene expression (osteogenesis and apoptosis), bone mineral density, microstructural and biomechanic
parameters.
Methods: We analyzed data from 12 subjects: 6 with osteoporotic hip fracture (OP) and 6 with hip osteoarthritis
(OA), as the control group. All subjects underwent medical history, analytical determinations, densitometry,
histomorphometric and biochemical study. The expression of 86 genes of osteogenesis and 86 genes of apoptosis
was studied in pool of bone samples from patients with OP and OA by PCR array.
Results: We observed that most of the genes of apoptosis and osteogenesis show a decrease in gene expression
in the osteoporotic group in comparison with the osteoarthritic group. The histomorphometric study shows a
lower bone quality in the group of patients with hip fractures compared to the osteoarthritic group.
Conclusions: The bone tissue of osteoporotic fracture patients is more fragile than the bone of OA patients. Our
results showed an osteoporotic bone with a lower capacities for differentiation and osteoblastic activity as well as a
lower rate of apoptosis than osteoarthritic bone. These results are related with structural and biochemical
parameters.
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Normal bone remodelling requires a balance between
bone formation and resorption and disruption of either
activity or both leads to metabolic bone disorders, being
osteoporosis the most prevalent one. In the process of
bone formation and resorption different regulatory sys-
tems are involved, mainly communication systems be-
tween different bone cells: osteoblasts, osteoclasts and
osteocytes [1].
Microarrays studies showed that the expression of sev-
eral genes is related with BMD and with osteoporotic
disease [2]. Bone remodelling is regulated by numerous
signalling pathways. It is becoming clear that bone for-
mation and homeostasis require at least six major uni-
versal signalling transduction pathways: Notch, Wnt,* Correspondence: merce_giner@yahoo.es
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reproduction in any medium, provided the orTGF/BMP, Hedgehog, steroid hormone receptor, and re-
ceptor tyrosine kinase [3,4]. Most signalling pathways
converge in a few transcription factors such as Runx2,
Osterix, Sox9 and AP-1 [5,6].
One of the best known processes of bone regulation is
OPG/RANKL/RANK that regulates directly the action
of osteoblasts and osteoclasts [7], and changes in the
production of osteoprotegerin (OPG) and/or RANKL
produces misbalances in bone remodelling which can
lead to a major formation or resorption depending on
the final balance between both proteins.
Apoptosis plays a critical role during embryonic limb
development, skeletal maturation, adult bone turnover by
modeling and remodeling processes, and during fracture
healing and bone regeneration. In humans, increased
osteocyte apoptosis has been correlated with sites of rapid
bone turnover [8], and osteoblast apoptosis plays an im-
portant role in bone development and maintenance. It istd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sembled at the resorption pit die by apoptosis. Further,
bone loss caused by sex steroid deficiency, glucocorticoid
excess, or aging is caused in part by osteoblast apoptosis [9].
As a result of the balance between bone formation and
resorption, bone structure may be modified and thus the
biomechanical properties which are determinant of bone
strength and fracture resistance.
Therefore, in the present study, we determined the al-
terations in the osteogenic and apoptotic activity on
bone samples from osteoporotic hip fracture patients
versus hip osteoarthritis patients. Also, we studied the
microstructural and biomechanical characteristics of tra-
becular bone in these patients.
Methods
Patients
The studied population consisted of two groups of pa-
tients. The first included 6 patients (1 man and 5 women)
with osteoporotic hip fractures (OP), between 62–87 years
old and the second one, 6 patients (2 men and 4 women)
with hip osteoarthritis (OA), between 55–78 years old.
Inclusion criteria in both groups were to be aged 55 or
over, not to lead a sedentary life, to walk for 3–4 hours
every week, to take more than 700 mg/day of calcium
(calculated by dietetic questionnaires) and not receiving
treatment with an influence on bone metabolism. The OP
group was made up by patients with an osteoporotic hip
fracture that required arthroplasty and the OA group by pa-
tients with osteoarthritis, admitted for elective hip
arthroplasty and not having presented an osteoporotic
fracture during their life. Exclusion criteria were malignant
diseases, hyperthyroidism, hyperparathyroidism, osteomal-
acia, previous bisphosphonate or systemic steroid treat-
ment or use of vitamin D supplements or current use of
hormone replacement therapy or any other drugs with ef-
fects on bone metabolism.
Patients were included in the study in a consecutive
manner as they were directed to arthroplasty by the
Trauma & Orthopedics Department in the University
Hospital “Virgen Macarena” of Seville, Spain.
All patients were included to participle in this study
and agreed their bone samples. The study was approved
by the Institutional Ethics Committee and written in-
formed consent was obtained from all the participants in
the study.
During the surgical procedure, a femoral osteotomy
was performed and the femoral head and neck were
removed.
Biochemical parameters
We obtained a fasting blood sample, in the first 48 h after
surgery, for analytical determinations of parameters related
to bone metabolism: calcium corrected for albumin levels,phosphorus, β- CrossLaps, aminoterminal propeptide of
type I procollagen (PINP), parathyroid hormone (PTH),
25-hydroxyvitamin D (25(OH)D) and insulin growth
factor-like (IGF-I).
Corrected serum calcium and phosphorus were measured
by an autoanalyzer DAX-96.
PTH, β-CrossLaps and PINP were analyzed by immuno-
assay by an autoanalyzer COBAS 601 (Roche, Spain).
Interassay CV <5.8%, <7.6% and <4.2% respectively.
25(OH)D were analyzed by direct competitive im-
munoassay by an autoanalyzer LIAISON (DiaSorin,
Italy). Interassay CV < 5.5%.
Serum IGF-I was measured by immunoassay by
IMMULITE (Siemens, Germany). Interassay CV < 3.9%.
Dual-energy X-ray absorptiometry (DXA)
Bone mineral density (BMD) was measured in the hip
and contralateral femoral neck by dual X-ray densitom-
eter with Hologic-DISCOVERY. CV in vivo 2.9% (fem-
oral neck) and 2.5% (total hip).
Microstructural and biomechanic bone study
The distal femoral region was analyzed without further
sample preparation by micro-CT, (SkyScan 1172) at
TrabeculaeW (San Cibrao das Viñas, Spain). Data sets
were rebuilt using a modified Feldkamp algorithm and
segmented into binary images (8-bit BMP images) using
adaptive local thresholding. Trabecular bone regions
were analyzed using the commercial software (Sky-Scan™
CT, 1.6.0) [10].
To evaluate the biomechanical properties we have
performed uniaxial compression tests using the IGFA sys-
tem (image-guided failure analysis). The variables were
quantified to describe the mechanical behaviour of bone
tissue including the maximum stress (σ), the maximum
strain (ε), and the Young’s modulus (E).
RNA extraction and cDNA synthesis
RNA was isolated from the femurs by using Trizol, following
manufacturer’s instructions (Invitrogen, CA, USA).
To carry out the PCR array, total RNA from 6 differ-
ent patients in each experimental group was pooled
(3 μg total) and the pool was reverse-transcribed with
RT2 First strand kit (SABiosciences, USA) according to
manufacturer’s instructions. For the study of OPG and
RUNx2 genes, aliquots of RNA (250 ng) were reverse-
transcribed with RT2 First strand kit (SABiosciences,
USA) according to manufacturer’s instructions.
PCR array and real time PCR
Human osteogenesis and Human apoptosis RT2 Profilertm
PCR Arrays (SuperArray, USA) were used to screen the
expression of multiple genes in human bone biopsies.
They were used according to the manufacturer’s protocol
Table 1 Anthropometric, DXA and biochemical
characteristics of the study population
Hip fracture Osteoarthritis
N 6 6
Age (year) 77.8 ± 4.5 65.4 ± 3.7
Sex (f/m) 5/1 4/2
BMI (body mass index) 29.69 ± 1.5 34.25 ± 2.2
Neck BMD (gHA/cm2) 0.59 ± 0.03 0.74 ± 0.08
Total hip BMD (gHA/cm2) 0.83 ± 0.04 0.88 ± 0.06
25(OH)D (ng/mL) 12.1 ± 2.7 15.4 ± 2.8
P1NP (ng/mL) 41.5 ± 6.04 41.8 ± 11.6
β-CrossLaps (ng/mL) 0.51 ± 0.1 0.36± 0.08
f/m . Female/male. BMD, bone mineral density.
Comparasion were assessed by t-Student test. Values are
mean ± standard error.
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were normalized with the less variable housekeeping gene
available in the array, beta-actin, and a significant
(p < 0.05). 3–fold change over control was the selected
criteria for an experimental gene expression change, simi-
larly to other studies of this kind [11]. Results were ana-
lyzed with th RT2 Profiler™ PCR Array Data Analysis
(http://www.sabiosciences.com/pcrarraydataanalysis.
php#Excel).
Duplicate plates were used.
To validate de PCR array, real time PCR was done with
cDNA from each patient, and was repeated three times for
each gene using SYBRGreen (Roche,) and the primers of
Runx2, osteoprotegerin and beta-actin (housekeeping gene)
were provided by QuantiTectPrimer Assay (Quiagen,USA).
Real-time PCR were performed in the ABI PRISM 7500
system (Applied Biosystems,USA). Results were expressed
in mRNA copy numbers, calculated for each sample using
the cycle threshold (Ct) value, and normalized against 18S
rRNA.Statistics
Results were analyzed with th RT2 Profiler™ PCR
Array Data Analysis (http://www.sabiosciences.com/
pcrarraydataanalysis.php#Excel).
Variables were tested for normality of distribution
using Kolmogorov-Smirnov test. To statistical signifi-
cance of the differences between the means of OP and
OA gene expression values in the real time PCR analysis
were determined by t-Student test. We used the statis-
tical package SPSS 18.0 (Illinois, USA). Statistical differ-
ences were set at p < 0.05. Results are presented as
mean ± standard error (SEM).Table 2 Structural data
Hip
fracture
n = 6
Osteoarthritis
n = 6
p
BV/TV (%) 30.5 ± 2.9 39.4 ± 6.5 NS
Tb.Th (mm) 0.2 ± 0.005 0.02 ± 0.02 NS
Tb.Sp (mm) 0.55 ± 0.02 0.46 ± 0.03 0.04
Tb.N (mm-1) 1.51 ± 0.12 1.90 ± 0.12 0.049
Tb.Pf (mm-1) 2.25 ± 1.18 −2.3 ± 2.19 NS
SMI 1.11 ± 0.26 −0.11 ± 0.74 NS
DA 3.38 ± 0.19 2.88 ± 0.34 NS
Young’s modulus
(Mpa)
406.1 ± 43.1 634.3 ± 161.7 NS
σ (Mpa) 8.28 ± 1.21 11.63 ± 2.94 NS
ε 0.03 ± 0.005 0.04 ± 0.004 NS
Values are mean ± standard error. NS = not statistically significant.
BV/TV: bone volume fraction; Tb.th: trabecular thickness; Tb.Sp: trabecular
separation; Tb.N: trabecular number; Tb.Pf: trabecular bone pattern factor; SMI:
structure model index; DA: degree of anisotropy; σ: maximum stress; ε:
maximum deflection.Results
We analyzed data from 12 patients: 6 with osteoporotic
hip fracture (OP) and 6 with hip osteoarthritis (OA), as
the control group, who fulfilled the enrolment criteria.
Clinical characteristics and laboratory data of the OP
and OA groups are summarized in Table 1.
In both groups, the anthropometric and biochemical
characteristics were comparable. Although patients with
fractures tended to be older than those with OA, age dif-
ferences did not seem to influence the results because
we found no statistical significant differences between
groups and also we found no correlation between age
and gene expression in either group.
OP patients had lower values of total hip bone mineral
density (BMD) (0.83 gHA/cm 2 ± 0.04 OP; 0.89 gHA/cm 2 ±
0.06 OA) and neck BMD (0.59 gHA/cm 2 ± 0.03 OP; 0.74
gHA/OA±0.08 cm 2) than the control group, and higher
bone remodelling serum marker, β-CrossLaps, 0.51 ng/mL±
0.1 (OP) vs. 0.36 ng/mL± 0.08 (OA) without rearchingstatistical differences. In all patients, the levels of 25 (OH) D
were < 20 ng/mL.
Histomorphometry and biomechanics results
Microstructural indices show a lower bone quality in the
group of patients with hip fractures compared to the
osteoarthritic group (Table 2).
We observed significant lower number of trabeculae
(Tb.N.) in the bone of hip fracture patients (1.5 mm-1 ±
0.1 vs 1.9 mm-1 ± 0.1; p = 0.049) and furthermore, these
patients also have a greater separation between trabeculae
(Tb.Sp) (0.55 mm± 0.46 vs. 0.02 mm± 0.03, P = 0.04). The
thickness of the trabeculae (Tb.Th) was similar in both
groups.
The trabecular pattern index (inverse of connectivity
index) showed higher values in the fractured patient
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a relative prevalence of tube-cylinder trabeculae in com-
parison to plate-form ones, was higher in the group of
patients with hip fracture, indicating a greater number
of trabeculae in tube-shaped cylinder, less resitant, in
these patients.
Biomechanical studies showed that the values of Young’s
modulus, maximum stress and maximum deflection, after
applying the compression test, were lower in patients
with hip fractures compared with osteoarthritic patients,
although these differences did not reach significance
(Table 2).
PCR array osteogenesis
We examined whether osteoporotic patients would have
any alterations in the osteogenesis in comparison with
osteoarthritic patients. If we consider biologically signifi-
cant variations when the induction or repression of the
gene is at least 3 times, we found that 23 genes, from 86
genes involved in osteogenesis, are altered (p <0.05). In
most cases, we observed a repression of these genes inTable 3 Osteogenic genes at least 3-fold upregulated or
downregulated in osteoporotic bone tissue
Gen
symbol
ID gen
(GeneBannk)
Function Fold
change
BGLAP NM_199173 Skeletal Development - 3.39
BMP5 NM_ 001718 Skeletal Development - 3.87
BMP6 NM_021073 Skeletal Development - 3.30
CDH11 NM_001797 Bone Mineral Metabolism - 3.30
COL14A1 NM_021110 Bone Mineral Metabolism - 9.54
COMP NM_000095 Bone Mineral Metabolism - 4.63
EGFR NM_005228 Cell growth and differentiation −5.28
FGF1 NM_000800 Cell growth and differentiation 3.3
FGFR1 NM_015850 Cell growth and differentiation - 5.95
FGFR2 NM_000141 Cell growth and differentiation - 5.63
IGF1R NM_000875 Cell growth and differentiation - 8.96
VEGFA NM_003376 Cell growth and differentiation 3.00
TGFBR1 NM_004612 Cell Proliferation - 6.31
TGFRB2 NM_003242 Cell Proliferation - 7.04
VCAM1 NM_001078 Cell adhesion Molecules - 8.36
MMP2 NM_004530 Extracellular matrix Proteases - 4.36
MMP8 NM_002424 Extracellular matrix Proteases 5.06
NFKB1 NM_003998 Transcription Factors and regulators - 3.06
SMAD2 NM_005901 Transcription Factors and
regulators
- 3.42
SMAD3 NM_005902 Transcription Factors and regulators - 5.25
SOX9 NM_000346 Transcription Factors and regulators - 5.00
RUNX-2 NM_004348 Transcription Factors and regulators - 2.94
TNF NM_000594 Transcription Factors and
regulators
- 9.18osteoporotic compared with the control bone (Table 3).
Only FGF1 and VEGFA, genes involved in cell cycle regu-
lation, are overexpressed (3.3 and 3.0-fold, respectively).
From the family of metalloproteases, only MMP8 was up-
regulated, and it is involved in inflammatory joint processes
(5.06-fold).
Among the down-regulated genes, it is necessary to
emphasize the osteocalcin gene (BGLAP) (− 3.39-fold), a
specific gene from osteoblastic cells which function is
bone mineralization, CDH11 (−3.3-fold) a typical adhe-
sion molecule of osteoblasts, Runx2 (−2.94-fold) which
is a factor of transcription essential for the maturation of
osteoblastic cells and BMP6 (−3.3-fold) that encodes a
protein of bone formation, also typical from osteoblastic
cells. The latter four genes are characteristic of osteo-
blastic cells and are suppressed on the macerated OP
bones.
We also showed down-regulation in several transcrip-
tion factors such as NFKB1, SMAD2, SMAD3, SOX9
and TNF, which in turn modulate gene expression of
several genes.
PCR array apoptosis
When analyzing array apoptosis, we observed that most
of the genes show a decrease in gene expression in the
osteoporotic group in comparison with the osteoarthritic
group (Table 4).
As known, apoptosis can be initiated either by the
death receptor-mediated pathway or the mitochondria-
mediated pathway. In our study, we found that both
pathways are altered on macerated OP bones. Of the 84
genes studied, 26 have a significant lower gene expres-
sion in the OP group vs. OA, and only two of them
show increased expression (p <0.05). Specifically, we ob-
served a lower expression of TNF receptor family genes
as CD40 (−7.7-fold OP vs. OA), LTBR (−3.3-fold),
TNFRSF11B (−3.5-fold), CD27 (−6.6-fold) and the TNF
ligand Family, TNF (−16.7-fold). At a mitochondrial
level, there are repressed genes such as BAD (−5.8-fold)
and slightly BAX (−1.2-fold).
Caspases are final effector enzymes of programmed
cell death. In the OP group, the caspases studied also
have a lower gene expression, observing a significant
biologically variation for caspase 9 (−6.1-fold OP vs.
OA) and caspases 4 and 5 (−5.3- fold and −5.9-fold-
respectively).
We have also observed the repression of genes such as
Bcl2 (−6.3-fold) and BAG1 (−3.62-fold), both of the
bcl-2 family and ABL1 (−6.8-fold) involved in the da-
mage response DNA.
In OP patients, we only observed an increased in the
gene expressions of BCL2A1 (9.66-fold) and BNIP1
(2.7-fold), both from the BCL2 family of anti-apoptotic
features.
Table 4 Apoptotic genes at least 3-fold upregulated or
downregulated in osteoporotic bone tissue
Gen
symbol
ID gen
(GeneBannk)
Function Fold
change
CD27 NM_001242 TNF Receptor Family −6.57
CD40 NM_001250 TNF Receptor Family −7.71
LTBR NM_002342 TNF Receptor Family −3.35
TNF NM_000594 TNF Receptor Family −16.76
OPG NM_002546 TNF Receptor Family −3.52
TRAF4 NM_004295 TRAF Family −3.72
CRADD NM_003805 CRAD Family −4.49
CASP1 NM_033292 Caspase Family −6.31
CASP4 NM_001225 Caspase Family −5.34
CASP5 NM_004347 Caspase Family −5.93
CASP9 NM_001229 Caspase Family −6.09
CASP10 NM_001230 Caspase Family −11.93
APAF1 NM_001160 CARD Family −2.65
CARD8 NM_0149959 CARD Family −3.45
NOD1 NM_006092 CARD Family −3.43
NOL3 NM_ 003946 CARD Family −4.89
RIPK2 NM_003821 CARD Family −3.96
DAPK1 NM_004938 Death Domain Family −5.92
BIRC2 NM_001166 IAP family −3.22
XIAP NM_ IAP Family −4.49
BAG1 NM_ 004323 Bcl2-Family −3.62
BCL2 NM_000633 Bcl2-Family −6.31
BCL2A1 NM_004049 Bcl2-Family 9.66
BCL2L11 NM_006538 Bcl2-Family −6.13
BNIP1 NM_001205 Bcl2-Family 2.74
BNIP2 NM_004330 Bcl2-Family −4.88
ABL1 NM_005157 p53 and DNA damage response −6.85
BRAF NM_004333 Anti-apoptosis −6.55
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chose two genes, with particular relevance to the activity
of bone remodelling, such as Runx2 and OPG. Runx2 is
the major transcription factor involved in osteoblast differ-
entiation, and the results of the osteogenesis array plate
indicate a down-regulation in OP vs. OA bone of this gene
(−2.94-fold, p <0.05) (Table 3). OPG is part of one of the
main systems of regulation of bone remodelling (OPG/
RANKL/RANK) and the array plate are decreased apop-
tosis expression in the OP group compared with the OA
group (−3.52-fold, p < 0.05) (Table 4).
When analyzed individually OPG and Runx2 gene, we
observed that the OP group has almost 2 times less ex-
pression of Runx2 and 6.9 times less OPG than the con-
trol group (p = 0.004), confirming the results of
osteogenesis and apoptosis arrays (Figure 1).Discussion
The osteogenic activity is mediated by multiple proteins
and may be altered by different circumstances. We in-
vestigated whether genes associated with this activity
may have a different expression in bone tissue of osteo-
porotic fracture patients versus osteoarthritis patients.
We have studied 86 genes related to osteogenic activity
and 84 to apoptosis. Most of them have a lower expres-
sion in osteoporotic bone than in osteoarthritic bone, in-
dicating that the bone tissue in osteoporosis is more
inert, having less transcriptional activity.
Regarding osteogenic activity, the macerated OP hip
bone has repressed typical genes of osteoblast cell. So
BGLAP (essential for bone mineralization), CDH11 (osteo-
blast adhesion molecule) and Runx2 (transcription factor
required for osteoblastogenesis), have a lower expression in
osteoporotic than arthritic bone, which is consistent with
decreased osteoblast differentiation and activity in osteo-
porosis bone. This finding agrees with previous results
[12,13], and low levels of osteocalcin published by
Napal et al. in stressful situation [14]. These results
were confirmed by the analysis of the expression of
Runx-2 by real-time PCR, significantly lower in samples
from OP patients, in comparison with samples from OA
patients.
Several TGF-β/BMP signalling pathway components
and modulator genes that influence osteoblast function,
bone remodelling and bone mineralization, were down-
regulated in OP bone, such as TGFBR1, TGFBR2, BMP5,
BMP6, SMAD 2 and SMAD3. Several authors agree with
these results, and it is consistent with decreased in the
bone turnover in OP bone [15-18].
Previous studies demonstrated that BMP6 was more po-
tent and consistent than BMP2 and BMP7 in inducing
osteoblast differentiation in primary hMSC [19], so that a
decrease in the expression of BMP6 in OP bone indicates a
minor osteoblast differentiation. In the other hand, BMP5
accelerates expression of hypertrophy markers which is of
relevance in both development and diseases such as osteo-
arthritis [20], this is consistent with the presence of higher
values in OA patients macerates against OP ones.
With regard to genes encoding the synthesis of
metalloproteinases, we have also found differences when
comparing the osteoporotic and arthrosic bone. The lack
of MMP8 is accompanied by synovial inflammation and
bone erosion in mice arthritis model, indicating that
MMP8 has a protective role in this disease. The fact of
finding higher expression levels MMP8 in OP patients
than OA may suggest an increased activity in inflamma-
tory joint in OA patients [21,22].
In cell cycle regulation, multiple receptors and modulators
of different activation pathways are involved. Among the
genes studied in this group, we obtained a decreased gene
expression of EGFR, FGFR1, FGFR2 and IGF1R in the OP
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Figure 1 Normalized mRNA levels for Runx2 and OPG in human femur of patients with OP and OA. Results are mean ± S.E.M: (n = 3). The
results reported in percentages of the variation referred to OA group. *p < 0.05 OP vs. OA.
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two of the three genes with an increased expression in the
OP group.
Epidermal growth factor receptor (EGFR) signalling
pathway is an important bone regulator and it primarily
plays an anabolic role in bone metabolism. A physiological
function of osteoblastic EGFR signalling is maintaining
the pool of osteoprogenitors at an undifferentiated stage
in bone. It is reported that blocking EGFR activity in
osteoblast lineage cells results in fewer osteoprogenitors
and leads to defective bone formation [23]. Fibroblast
growth factors (FGFs) are polypeptides that control the
proliferation and differentiation of various cell types in-
cluding osteoblasts. FGFs are also strong inducers of
angiogenesis, necessary to obtain oxygen and nutrients
during tissue repair [24]. Some authors have described
that the administration of FGF1 increases new bone for-
mation and bone density [25]. Our findings about a minor
expression of receptors in OP bone indicate a reducedcapacity for bone regeneration in these patients, which
tries to compensate with increased expression of the lig-
and FGF1. We also found high levels of VEGF in OP bone
as other authors who described an increase of mRNA
expression of VEGF in femoral neck fracture versus
nontraumatic femoral head in humans [26].
All these results taken together suggest that osteo-
blastic activity is decreased in osteoporotic bone and
bone formation rate is lower in OP than in OA bone.
The human apoptosis PCR array profiles the expression
of 84 key genes involved in apoptosis or programmed cell
death. We have observed a down-regulation in 26 genes
and upregulation in only two of them.
The two major pathways of apoptosis are the extrinsic
(Fas and other TNFR superfamily members and ligands)
and the intrinsic (mitochondria-associated) pathways
[27]. We found no differences in the expression of genes
related to the FasL family but we showed a lower expres-
sion of genes of the TNF family in OP bone, such as
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are essential in mediating a broad variety of immune
and inflammatory responses [28], consistent with their
increased gene expression in OA patients rather than in
OP patients.
Caspases are proteases that cleave intracellular proteins
and are required to carry out apoptosis [29]. In OP group,
we found a down-regulation in all caspases studied, being
biologically significant decreases in the expression of
caspases −1, -4, -5, -9 and −10, indicating that in the OP
group there is a clear decrease in apoptotic activity. The
activation of these caspases requires binding to specific
cofactors, caspases possess different domains, containing
death-effector domains (DED) or caspase recruitment do-
mains (CARD) [30] and we also observed a down-
regulation in some of these cofactors, specifically with
Apaf-1, CARD8, NOD1, NOL3, RIPK2 and DAPK1, in
OP bone.
Bcl-2 proteins are a family of cytosolic proteins in-
volved in the mitochondrial pathway of apoptotic and
these can be either anti or pro-apoptotic. They act as a
sensor of cellular damage. At present, regulation of
apoptosis by Bcl-2 family members is complex and not
fully understood because most cells express a variety of
antiapoptotic and proapoptotic Bcl-2 proteins, and the
regulation of their interactions dictates survival or com-
mitment to apoptosis [31]. Our studies show a decrease
in the expression of members of the Bcl-2 anti-apoptotic
family such as BAG1, BCL2 (one of the most important
and well known), BCL2L11 and OP BNIP2 in bone and
increased the expression of BCL2L11 and BNIP1. We
suggest that the balance of the expression of these genes
can lead different cells in the osteoporotic bone towards
apoptosis inhibition. Although, we were waiting high
levels expression of caspases, they found low, this might
be due to the differences type of cells in the bone
samples (osteoblasts, osteocytes, mesenchymal stem
cells . . .). Some authors described increased apoptosis of
osteocytes after an osteoporotic fracture [32], but the
apoptosis of osteoblasts was not altered. Furthermore, it
seems that an increase in apoptosis indicates an increase
of bone remodeling, and we observed an osteoporotic
bone with low transcription level and consequently with
low bone remodelling [8].
OPG plays essential roles in the osteoblast cell, on the
one hand it inhibits bone resorption, joining the recep-
tor activator for nuclear factor _B ligand (RANKL) [33]
and on the other hand, it can also bind and antagonize
the activity of the TNF-related apoptosis-inducing ligand
(TRAIL) [34]. We found decreased levels of OPG ex-
pression in OP bone, in PCR array and also to check
real-time PCR.
The histomorphometry data obtained indicate that OP
bone is of lower quality than OA, observing a smallernumber of trabeculae, greater separation between them
and poorer connectivity [35]. These characteristics indi-
cate that OP bone is more fragile and such fragility is
determined by a worse bone structure. We could not
correlate these values with any of the genes studied, al-
though some authors suggest a relationship between low
expression of Runx2, in biopsies from the iliac crest
from patients with male idiophatic osteoporosis, and a
significant decrease in the number of trabeculae and
conectivity density [36], data that support our findings.
Our study has some limitations. Firstly, we studied tra-
becular bone, which may behave differently of cortical
bone and secondly we present a relatively low number of
patients.
These results open a wide field of research in the treat-
ment of osteoporotic and arthritic disease. Noting the
different gene activities that are in both conditions, we
can deepen the study of each of these genes looking for
the best candidate as a therapeutic target. In our work,
we point out the genes with differential expression and
also we relate gene activity to structural and biochemical
differences in bone.
Conclusions
In summary, our findings lead us to conclude that bone tis-
sue of osteoporotic fracture patients presented worse
microstructural characteristics which make them more fra-
gile than the bone of OA patients, in line with other au-
thors [35]. This may be related to an imbalance in bone
remodelling that is conditioned by a lower expression of
genes encoding proteins that promote osteogenic activity.
The result is a bone with a lower capacity for differenti-
ation and osteoblastic activity as well as decreased activity
of bone remodelling and mineralization capacity. This
bone also shows data suggesting a lower rate of apoptosis.
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